A case of bupropion-induced stuttering

General Hospital Psychiatry

Volumn 35, Issue 5, 2013, Pages 574.e7-574.e8

  Fetterolf, Frank ^a   Marceau, Michael ^a  

^a Geisinger Health Geisinger Commonwealth School of Medicine   (United States)

Author keywords

Bupropion; Dopamine; Stuttering

Indexed keywords

AMFEBUTAMONE; CITALOPRAM;

ADULT; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DROWSINESS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERVIEW; MAJOR DEPRESSION; PSYCHOTHERAPY; SOMATIZATION; STUTTERING;

BUPROPION; DOPAMINE; STUTTERING;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MIDDLE AGED; STUTTERING;

EID: 84884149114     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.07.003     Document Type: Article

References (25)

1. Brady J.P. Drug-induced stuttering: a review of the literature. J Clin Psychopharmacol 1998, 18(1):50-54.
2. Nurnberg H.G., Greenwald B. Stuttering: an unusual side effect of phenothiazines. Am J Psychiatry 1981, 138(3):386-387.
3. Garvey M.J., Tollefson G.D. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry 1987, 44(3):269-272.
4. Masand P. Desipramine-induced oral-pharyngeal disturbances: stuttering and jaw myoclonus. J Clin Psychopharmacol 1992, 12(6):444-445.
5. Makela E.H., Sullivan P., Taylor M. Sertraline and speech blockage. J Clin Psychopharmacol 1994, 14(6):432-433.
6. McCall W.V. Sertraline-induced stuttering. J Clin Psychiatry 1994, 55(7):316.
7. Christensen R.C., Byerly M.J., McElroy R.A. A case of sertraline-induced stuttering. J Clin Psychopharmacol 1996, 16(1):92-93.
8. Brewerton T.D., Markowitz J.S., Keller S.G., Cochrane C.E. Stuttering with sertraline. J Clin Psychiatry 1996, 57(2):90-91.
9. Guthrie S., Grunhaus L. Fluoxetine-induced stuttering. J Clin Psychiatry 1990, 51(2):85.
10. Meghji C. Acquired stuttering. J Fam Pract 1994, 39(4):325-326.
11. Fava M., Rush A.J., Thase M.E., et al. 15 years of clinical experience with bupropion HCL: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005, 7(3):106-113.
12. Stahl S.M., Pradko J.F., Haight B.R., et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004, 6(4):159-166.
13. American Psychiatric Association Diagnostic and statistical manual of mental disorders (DSM-IV) 1994, 65. American Psychiatric Association, Washington. 4th ed.
14. Market K., Montague J., Buffalo M., Drummond S.S. Acquired stuttering: descriptive data and treatment outcome. J Fluency Disord 1990, 15(1):21-33.
15. Schatzberg A.F., Cole J.O., Blumer D.P. Speech blockage: a tricyclic side effect. Am J Psychiatry 1978, 135(5):600-601.
16. Burns D., Brady J.P., Kuruvilla K. The acute effect of haloperidol and apomorphine on the severity of stuttering. Biol Psychiatry 1978, 13:255-264.
17. Maguire G.A., Riley G.D., Franklin D.L., Gottschalk L.A. Risperidone for the treatment of stuttering. J Clin Psychopharmacol 2000, 20(4):479-482.
18. Wu J.C., Maguire G., Riley G., Kreator D., Tang C., Fallon J., Najafi A. Increased dopamine activity associated with stuttering. NeuroReport 1997, 8(3):767-770.
19. Arias H.R., Santamaria A., Ali S.F. Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol 2009, 88:223-255.
20. Horn A.S. Structure-activity relations for the inhibition of catecholamine uptake into synaptosomes from noradrenaline and dopaminergic neurones in rat brain homogenates. Br J Pharmacol 1973, 47(2):332-338.
21. Raiteri M., Del Carmine R., Bertollini A., Levi G. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol 1977, 41(2):133-143.
22. Giros B., Wang Y.M., Suter S., McLeskey S.B., Pifi C., Caron M.G. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 1994, 269(23):15985-15988.
23. Gu H., Wall S.C., Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 1994, 269(10):7124-7130.
24. Eshleman A.J., Carmolli M., Cumbay M., Martens C.R., Neve K.A., Janosky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 1999, 289(2):877-885.
25. Morón J.A., Brockington A., Wise R., Rocha B.A., Hope B.T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock out mouse lines. J Neurosci 2002, 22(2):389-395.